As hep C revenues decline, investors ask: Who is Gilead?
As sales of its hit Hep C drugs decline, Gilead faces an uncertain future. Where to next for a company defined by one blockbuster franchise?
As sales of its hit Hep C drugs decline, Gilead faces an uncertain future. Where to next for a company defined by one blockbuster franchise?
A federal jury has awarded $2.54 billion in royalties to Merck, ruling against Gilead in a monumental patent infringement case involving two blockbuster hepatitis C drugs. The kicker? The judge has the power to triple that figure.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Also, a reverse merger by Synta Pharmaceuticals and Madrigal Pharmaceuticals will create a company that focuses on non-alcoholic steatohepatitis and Kaiser Permanente has launched a biobank to develop new diagnoses and treatment plans.
Sovaldi, cancer theft, J&J makes move in Hepatitis C, and tough days for health insurance companies in Oregon - and more.
There’s a new drug regimen being touted as a potential cure for a dangerous liver virus that causes hepatitis C. But it costs $84,000 — or $1,000 a pill. And that price tag is prompting outrage from some consumers and a scramble by insurers to figure out which patients should get the drug —and who pays for it. […]